CumULA Stand Stress Description Description <thdescription< th=""> <thdescription< th=""> <th< th=""><th>PFI</th><th>ZER</th><th>INC</th><th>. NYSE</th><th>E-PFE</th><th></th><th></th><th>R P</th><th>ecent Rice</th><th>29.68</th><th>B P/E Ratio</th><th>o 17.</th><th>5 (Traili Medi</th><th>ing: 18.0) ian: 15.0)</th><th>RELATIV P/e rati</th><th>0.9</th><th>3 DIV'D</th><th>3.5</th><th>5%</th><th>/ALUI LINE</th><th></th><th></th></th<></thdescription<></thdescription<>	PFI	ZER	INC	. NYSE	E-PFE			R P	ecent Rice	29.68	B P/E Ratio	o 17 .	5 (Traili Medi	ing: 18.0) ian: 15.0)	RELATIV P/e rati	0.9	3 DIV'D	3.5	5%	/ALUI LINE		
EFV 1 state (110) Leading of the large	TIMELIN	VESS 3	Raised 1	/3/14		36.9 27.9	38.9 22.0		28.6 22.2	27.7 22.2	24.2 14.3	19.0 11.6				32.5 25.3						
CHULL AS 1 Marked Line (1) Comparison of the second of the s	SAFET				10).0 x "Cash	n Flow″ps	sh					IF							2017	2010	64
201/14 PROJECTIONS This Gas Mark Common Section Sectin Sectin Sectin Section Section Section Sectin Section Section S				/4/14	Options:	elative Pric Yes	e Strength															48
Price cash Finan Price				ONS	Shaded		ates recess															40
alter Technics visual alter Technics alter Technics visual alter Technics alter Technics visual alter Technics visual alter Technics visual alter Technics			A	nn'l Total	<u> </u>			111 ¹¹ 1.1	1 ¹¹ 11	1,11,11,11						ահուր։	•••••••••••••••••••••••••••••••••••••••					24
alter Technics visual alter Technics alter Technics visual alter Technics alter Technics visual alter Technics visual alter Technics visual alter Technics	ligh Low	40 (-	+35%)	10%	ده. منهنهای و	••••					*****			ի ուրելու	1.1.1.							20 16
Num Num <td></td> <td></td> <td>,</td> <td>1 /0</td> <td>1</td> <td>•••</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>լիր</td> <td>-11-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-12</td>			,	1 /0	1	•••						լիր	-11-									-12
Num Num <td>o Buy</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>•••••••</td> <td></td> <td>8</td>	o Buy							•••••••														8
Number of the second	Options o Sell	0 1 1	1 0 0	11 1 0					,	••••••••••••••••	·. · · ·											_6
gr mot motor motor <t< td=""><td></td><td>tional I</td><td>Decisio</td><td>ns</td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>•••••••</td><td></td><td>•••••••</td><td>•••••</td><td>••••</td><td></td><td>% 10</td><td>THIS \</td><td>/L ARITH.*</td><td></td></t<>		tional I	Decisio	ns	-								•••••••		•••••••	•••••	••••		% 10	THIS \	/L ARITH.*	
$ \begin{array}{c} 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 $	to Buy	669	766	813																9.5	25.1	E
988 998 990 2000 2001 2001 2001 2011 2012 2013 2014 2015 CVLUE UPUE UPUE UFUE CF 8.0 104 115 155 155 252 253 251 252 253 251 252 253 153 253 253 253 153 153 253 253 153 </td <td>to Sell Hld's(000)</td> <td></td> <td></td> <td></td> <td></td> <td>6 -</td> <td></td> <td></td> <td>╢╢╢╢</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>11111111</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>F</td>	to Sell Hld's(000)					6 -			╢╢╢╢							11111111						F
80 1.02 1.18 1.51 1.72 2.24 2.30 2.92 2.30 1.14 1.23 1.15	1998				2002	2003	2004	2005	2006	2007	2008	2009		2011	2012	2013	2014	2015	© VAL	ue line p	UB. LLC	17-19
57 37 402 135 175 122 222 226 230 115 123 130 111 126 156 166 152 30 31 44 35 35 36 28 28 28 28 28 28 28 156 166 116 128 116 122 116 122 116 122 116 122 116 122 116 122 116 122 116 126						1															ch	8.1 2.2
25 31 36 44 52 60 88 76 88 116 128 80 72 80 83 98 16 100 <						1											1			•		3.2 2.3
227 231 255 2347 651 3247 652 476 376 324 175 184 175 175 184 175 184 175 184 175 184 175 184 175 184 175 186 175 187 175 184 175 186 175 175 175 175 175 175 175 175 175 176 175 <td< td=""><td>.25</td><td>.31</td><td>.36</td><td>.44</td><td>.52</td><td>.60</td><td>.68</td><td>.76</td><td>.96</td><td>1.16</td><td>1.28</td><td>.80</td><td>.72</td><td>.80</td><td>.88</td><td>.96</td><td>1.04</td><td>1.10</td><td>Div'ds D</td><td>ecl'd per</td><td>sh ^B∎</td><td>1.2</td></td<>	.25	.31	.36	.44	.52	.60	.68	.76	.96	1.16	1.28	.80	.72	.80	.88	.96	1.04	1.10	Div'ds D	ecl'd per	sh ^B ∎	1.2
820 8270 6374.0 7270 7830 7280.0 7870.0						1											1			• •		
286 283 286 134 126 148 128 87 61 99 55 104 101 117 385 338 endiate PE Eation 1 VPTAL STRUCTURE as of 30114 305 335 446 6505 517 518 5105 5105 6100 6600 6700	3882.0														_					· ·		6300.
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	51.2					1													-			16
$\begin{aligned} & \text{PTAL STRUCTURE a of 301'14} & \text{iss} first 5028 is 437' 440' 450' 5000 is 756' 450' 450' 450' 450' 450' 450' 450' 450$						1																1. 2 7
Bit Debt S27649 mill. Due in 5 Yrs 514885 mill. 48.95, 41.95, 41.95, 42.95						1.9%											10200	18000			leiu	
$ \begin{array}{c} 1686.3 \\ 1680.1 \\ 1680$	otal D	ebt \$369	968 mill. D	Due in 5 Y	/rs \$1458												1		•			51.0
$ \begin{array}{c} 161.6 \\ 120.7 \\ 122.8 $	T Deb	t \$27649) mill. I	_T Interes						5200.0	5090.0		8487.0		7611.0	6410.0	1		Deprecia	ation (\$mi		60
ases, Uncapitalized Annual rentials \$204.0 mil 30.7% 28.28 31.0% 31.5% 16.5% 17.2% 11.2					(2070 0	. eap .,								-								145
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	eases	. Uncapi	italized A	nnual ren	ntals \$204	.0 mill.											1					27.0
$\begin{array}{c c c c c c c c c c c c c c c c c c c $							13236					-					1		Working	Cap'l (\$n		350
Jummon Stock 6,378,718,233 sh. of \$5074Jimon Stock 6,378,718,233 sh. of \$5074Jimon Total Cap132 (38,2298)Jimon Total Cap133 (38,2298)Jimon Total Cap133 (38,2298)Jimon Total Cap133 (38,2298)Jimon Total Cap133 (38,2298)Jimon Total Cap133 (38,2298)Jimon Total Cap133 (38,2298)Jimon Total Cap133 (38,288)Jimon Total Cap1Jimon Total Cap1J	ensio	n Assets	5-12/13 \$.	21.1 DIII. (Oblig. \$2	5.6 DIII.											1		-	•		2000
cord SP(14)23.6% $23.2%$ $32.6%$ $62.8%$ $55.6%$ $6.0%$ Return on Shr. Equity $53.6%$ SM Assets32.70832.40833.61/4 $33.61/4$ $31.66%$ $32.6%$ 3	Commo	on Stock	6 378 71	18 203 sh	e.									-	-							13.0
IRRENT POSITION2012201331/1431%37%48%52%106%64%74%72%68%61%58%Alt Divds to Net Prof5servables327032408338173381733%37%48%52%106%64%74%72%68%58%61%58%Alt Divds to Net Prof5servables327032408338177338177 <td< td=""><td>is of 5/</td><td>5/14</td><td></td><td>,</td><td></td><td></td><td>23.6%</td><td>22.9%</td><td>21.0%</td><td>23.5%</td><td>13.9%</td><td>9.6%</td><td></td><td>-</td><td>-</td><td>14.9%</td><td>14.0%</td><td>15.0%</td><td>Return o</td><td>on Shr. Eq</td><td>uity</td><td>15.0</td></td<>	is of 5/	5/14		,			23.6%	22.9%	21.0%	23.5%	13.9%	9.6%		-	-	14.9%	14.0%	15.0%	Return o	on Shr. Eq	uity	15.0
(MILL) ski Assets32708 1277832408 937633881 9376BUSINESS: Filter Inc. is a research-based, global biopharmaceuti- cal company engaging in the discovery, development, manufacture, vac- rines, Assetscines. Oncology, and Consumer Healthare (VOC), and Global E tabilished Pharmaceutical (GPP). Top-selling products '13. Lyrk rent Assetscines. Oncology, and Consumer Healthare (VOC), and Global E tabilished Pharmaceutical (GPP). Top-selling products '13. Lyrk ranaging operations through a new structure consisting of three businesses: Global Innovative Pharmaceutical (GP). Global Model (GPP). Top-selling products '13. Lyrk ranaging operations through a new structure consisting of three businesses: Global Innovative Pharmaceutical (GP). Global Mill Pharmaceutical (GP). Global E tabilished Pharmaceutical (GP). Global Mill Pharmaceutical (GP). Global Mill Pharmaceutical (GP). Global Mill Pharmaceutical (GP). Global Mill Pharmaceutical (GP). Top-selling products '13. Lyrk or list of the table. The drug maker confirmed that after being rejecter tival AstraZeneca. Pfizer sweetened its takeover proposal on all four advances, the lat datout S120 billion in cash and stock. However, Astra wasn't convinced that it would not at the Mill 200 figure a dequately valued its prospects. ish regulation, it is not permitted to matemother dating back to the fourti- tish regulation, it is not permitted to matemother dating back to the fourti- ish regulation, it is not permitted to matemother dating back to the fourti- tish regulation, it is not permitted to matemother dating back to the fourti- tish regulation, it is not permitted to matemother dating back to the fourti- tish regulation, it is not permitted to matemother dating back to the fourti- tish regulation, it is not permitted to matemother for six months. <br< td=""><td></td><td></td><td></td><td></td><td></td><td>3/21/1/</td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td></td><td></td><td></td><td></td><td>6.5</td></br<>						3/21/1/	1										1					6.5
 nearbing lessibility of the second sec	(\$MI	LL.)																				
her 1 2926 B313 B447 internt Assets 61415 5544 57783 1400 556///1415 </td <td>Receiva</td> <td>ables</td> <td>1</td> <td>2378</td> <td>9357</td> <td>9399</td> <td></td>	Receiva	ables	1	2378	9357	9399																
Initial Assets 01413 30244 244 3073 Inter Payable 4224 6027 3074 54 4264 3234 256 6.67	Other		,	9266	8313	8447																
bet Dué642460279319Disnesses: Global Innovative Pharmaceutical (GPI), Global Vac-York, N1 1007. Tel: 212-733-2323. Internet: www.pitzer.comPrizer's2336624790Prizer'sproposedmega (last)MustersSizer'sPrizer'sPrizer'sproposedmega (last)MustersSizer'sPrizer's																						
Interest288192336624790FiltersProposed integed usar with and pointsDisters saw sates declined by 21/3 and 13INUAL RATESPastEst d'11-13 maker confirmed that after being rejected on four separate approaches, it would no longer be pursuing a merger with British invial AstraZeneca. Pfizer sweetened its take coming on May 19th in a deal valued at about \$120 billion in cash and stock, at about \$120 billion in cash and stock, at about \$120 billion in cash and stock, 1200 1200 1200 1200 13007Full testWe view the longer-term story moi particularly its portfolio of drugs in devel- or particularly its portfolio of drugs in devel- outterment. Pfizer indicated that it would no tatempt a hostile takeover and under Brit- is regulation, it is not permitted to make anther offer for six months.We view the longer-term story moi fold. Pfizer appears well positioned to r ord of developing and marketing its pro- ucts, and with a well-stocked pipeline is regulation, it is not permitted to make and the 33 31 19 1.11 to 23 42 44 120 1261123 4545501223 4244501436503914365010153645441618181722222018.001618.001818.001819.011819.022010.022010.022011.02.0212.02.0214.01 <t< td=""><td>Debt D</td><td></td><td></td><td>6424</td><td>6027</td><td>9319</td><td>busines</td><td>sses: Glo</td><td>bal Innc</td><td>vative Pha</td><td>rmaceu</td><td>utical (GI</td><td>P), Glob</td><td>al Vac-</td><td>York, N</td><td>Y 10017.</td><td>Tel.: 212</td><td>2-733-232</td><td>23. Intern</td><td>et: www.</td><td>pfizer.co</td><td>m</td></t<>	Debt D			6424	6027	9319	busines	sses: Glo	bal Innc	vative Pha	rmaceu	utical (GI	P), Glob	al Vac-	York, N	Y 10017.	Tel.: 212	2-733-232	23. Intern	et: www.	pfizer.co	m
NUMLARIESPastPast Est of 11-13 hange (persi)maker confirmed that after being rejected on four separate approaches, it would no heiged to lighten the blow, we do not be lieve it will be enough to avoid a fourt rival AstraZeneca. Pfizer sweetened its take over proposal on all four advances, the ust coming on May 19th in a deal valued at about \$120 billion in cash and stock.Lyrica franchise (+10%) h lieve it will be enough to avoid a fourt is consecutive year of revenue decline. Bass on our current model, we anticipate a 4 pullback in the top line in 2014.at at muter Marst Jun.30 Sep.30 Dec.31Full real 11502 fi308Full store its top 11.2Full tabout \$120 billion in cash and stock.We view the longer-term story moi pullback in the top line in 2014.at at at at at at at muter Marst Jun.30 Sep.30 Dec.31Full regulation, it is not permitted to make store its top line over the 3 - to 5-year pu attempt a hostile takeover and under British regulation, it is not permitted to make atter of 2011. While the pace of erosion has decelerated somewhat in recenti tom store its shigh-quality stock is ranked (Average) for Timeliness. We view the has decelerated somewhat in recenti has decelerated somewhat in recenti has decelerated somewhat in recenti tom store store seeking drug exposure. Pfiz maintains superior marks for Safety (toward trend dating back to the fourth quarter of 2011. While the pace of erosion has decelerated somewhat in recenti tom sfrom several core franchises, the company continues to be plaqued by in- ad to 18 and tab. 19 and tab. 19 and tab. 1000 from and toward trend dating back to the fourth tab. 22 and tab. 19 and tab. 19 and t		t Liab.																				
manage person10 Trs.5 Trs.10 Tr-19market person4.5%3.5%-5.0%ach Flow"3.0%-1.0%4.5%ach Flow"3.0%-1.0%4.5%ach Flow"5.5%-5.0%ach Maras Jun.305.0%5.0%al Maras Jun.305.0%1.11al Maras Jun.305.0%1.0%al Maras Jun.305.0%1.																						
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Sales	u ,	4.5	5% 3.	.5%	5%	on f	our se	epara	te appi	roach	les, it	woul	ld no	helpe	ed to	lighte	n the	blow	, we o	do no	t be
al- darQUARTERLY SALES (\$ mill.) mar.31 Jun.30 Sep.30 Dec.31Full Year HFull tabout \$120 billion in cash and stock.We view the longer-term story mon favorably. As generic pressures aba and new franchises are brought into th favorably. As generic pressures aba and mar.31 Jun.30 Sep.30 Dec.31Full Year H1116502 16984 17193 16746 67425 121485 t 5057 13976 15068598861312410 12973 12643 13558515841411353 12500 12100 13347493001511000 12000 12000 13000480001611128.33.31.191.11.23.42.41.20.12.23.31.19.11.28.33.31.19.11.23.42.44.36.50.50.33.50.50.34.50.50.35.50.36.50.36.50.37.45.45.44.45.50.501.90.34.45.33.31.31.31.33.31.34.34.35.50.36.50.37.45.45.44.33.50.34.45.35.50.36.50.37.50.38.50.39.40.45.45	Cash I	Flow" as	3.0 -1.5	% -1	0% .0%	4.5% 9.5%																
al- darQUARTERLY SALES (\$ mill.) mar.31 Jun.30 Sep.30 Dec.31Full Year HFull tabout \$120 billion in cash and stock.We view the longer-term story mon favorably. As generic pressures aba and new franchises are brought into th favorably. As generic pressures aba and mar.31 Jun.30 Sep.30 Dec.31Full Year H1116502 16984 17193 16746 67425 121485 t 5057 13976 15068598861312410 12973 12643 13558515841411353 12500 12100 13347493001511000 12000 12000 13000480001611128.33.31.191.11.23.42.41.20.12.23.31.19.11.28.33.31.19.11.23.42.44.36.50.50.33.50.50.34.50.50.35.50.36.50.36.50.37.45.45.44.45.50.501.90.34.45.33.31.31.31.33.31.34.34.35.50.36.50.37.45.45.44.33.50.34.45.35.50.36.50.37.50.38.50.39.40.45.45	Divider	ids	5.5 8 5	5% -5. 6% 4	.0% .0%	6.5% 5.0%	take	over p	oropos	al on a	ıll foı	ur adv	vances	s, the	on o	ur cui	rent	model	l, we	antici		
dar Mar.31Jun.30Sep.30Dec.31Year YearHar about 37.05Difficit Star Particularly its portfolio of drugs in devel- drugs in devel- to pment. Pfizer indicated that it would not attempt a hostile takeover and under Brit- ish regulation, it is not permitted to make another offer for six months.Full four allow 12000However, Astra wasn't convinced that the figure adequately valued its prospects, particularly its portfolio of drugs in devel- 	Cal-					1	last	comin	ig on	May 1	9th i	n a d	eal va	alued	pullb	ack ir	ı the t	top lin	ie in 2	2014.	-	
111116502169441/193167466742511214885150571397615068589861131241012973126431355851584114113531250012100133474930011511000120001300048000116110001200013000480001161100012000130004800011611000120001300048000111.28.33.31.19111.23.42.41.20112.23.42.41.20113.36.50.39.40115.45.44.45114.36.45.44.45.50.50115.45.50116.45.44.45.70116.45.44.41.20.165115.45.50115.45.50.50.190116.45.44.45.45.45.45.45.45.46.472.41.20.16.45.44.45.50.50.45.45.45.50.50.190.44.45.45.45.45.45.45.45.46.46<	ndar	Mar.31	Jun.30	Sep.30	Dec.31	Year																
113124101297312643135585158411411353125001210013347433001151100012000130004800013aiEARNINGS PER SHARE AFull11.28.33.31.191.1112.23.42.41.201.26111.28.33.31.191.11122.23.42.41.201.65112.23.42.41.201.65113.36.45.44.451.70114.36.45.44.451.70115.45.44.451.70114.20.20.20.501.90114.20.20.20.20.20114.20.20.20.20.80124.24.24.24.24124.24.24.24125.22.22.22126.22.22126.22.22126.24.24126.23.24127.24.24128.24.24129.24.24129.24.24129.24.24129.24129.24.24129.24129.24129.24							figur	e ad	equat	ely va	lued	its	prosp	pects,	and	new	francł	nises	are b	rough	t into) th
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2013	12410	12973	12643	13558	51584																
IndexFunctionFunctionFunctionFunctionFar-EARNINGS PER SHARE AFullFullFullFullFunctionMar.31Jun.30Sep.30Dec.31FunctionFunctionFunctionM1.28.33.31.191.11M2.23.42.41.201.26M3.36.50.39.401.65M14.36.45.44.451.70M15.45.50.501.90M15.45.50.501.90M16.45.44.501.70M15.45.50.501.90M16.45.44.501.70M16.45.44.451.70M16.45.44.45M17.20.20.20M18.18.18.18M19.22.22.22M10.18.18M11.20.20.20M11.20.20.20M12.22.22.22M13.24.24M14.26.26M14.26.26M14.26.26M14.26.26M14.26.26M14.26.26M14.26.26M14.26.26M14.26.26M14.26.26 <tr< td=""><td>2014</td><td></td><td>12500</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr<>	2014		12500																			
darMar.31Jun.30Sep.30Dec.31Year11.28.33.31.191.1112.23.42.41.201.26113.36.50.39.401.65114.36.45.44.45115.45.45.50.50115.45.50.501.90115.45.44.45115.45.50.50115.45.50.50116Image in size in the near term. In the March period, total revenue declined 9% year over year in Q1115.45.44.45.50.50.16Image in size in the near term. In the March period, total revenue declined 9% year over year in Q1116.45.44.45.50.50.16Image in size in the near term. In the March period, total revenue declined 9% year over year in Q1116.45.44.45.50.50.46Mar.31Jun.30.40Nextern of 2011. While the pace of erosion has decelerated somewhat in recent quarters, thanks to improved contributions from several core franchises, the company continues to be plagued by intense generic competition on Lipitor and Viagra (in Europe). These former block-111.20.20.20.22.22.22.23.24.24.24.26.26113.24.24.26.26124.26 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>ish 1</td> <td>egula</td> <td>tion,</td> <td>it is no</td> <td>ot per</td> <td>rmitte</td> <td></td> <td></td> <td>ord o</td> <td>of dev</td> <td>elopin</td> <td>ng ang</td> <td>l mar</td> <td>keting</td> <td>g its j</td> <td>pro</td>							ish 1	egula	tion,	it is no	ot per	rmitte			ord o	of dev	elopin	ng ang	l mar	keting	g its j	pro
11.28.33.31.191.1112.23.42.41.2013.36.50.39.4014.36.45.44.4515.45.44.45161.70175.45.44.45176.45.44.45176.45.45.5018aQUARTERLY DIVIDENDS PAID.5019aQUARTERLY DIVIDENDS PAID.5019a.44.1619a.45.44.45.50.50.45.45.50.45.45.50.46.50.50.47.48.48.48.49.49.40.41.41.20.20.20.20.20.20.20.21.22.22.22.22.22.23.24.24.24.24.24.26.41.26.26.26.26.27.22.28.81.29.56.20.20.21.22.22.22.22.22.24.24.25.26.26.26.26.26.27.29.28.83.29.56.20.30<	cal- endar												v to	ner-								
111 .23 .42 .41 .20 1.90 Has decelerated somewhat in recent recent (sales increased 10% year over year in Q1 101 .45 .45 .50 .50 1.90 Has decelerated somewhat in recent (Average) for Timeliness. We view the 102 .20 .20 .20 .80 .72 .80 .80 for Sales investors seeking drug exposure. Pfiz 112 .22 .22 .22 .22 .20 .80 .80 .80 .80 .80 .80 .80 .80 .80 .80 .80 .80 .80 .80 .80	2011						sist	in th	e nea	r tern	ı. In	the M	Ĭarch	peri-	tinue	e. îW€	e are	e par	ticula	rly e	ncour	age
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2013	.23	.42 .50				od,	total	reven	ue dec	lined	1 9 %	year	over	with	the c	compa	ny's g	growin	gonc	ology	un
And A	2014	.36	.45	.44	.45	1.70	year dowi	ιο 1ward	ə11. tren	4 Dill d datin	ion, g ba	cont ck to	the fo	g a ourth	(sale: This	s mere higi	eased h- qua	10% y	year o stock	ver ye is i	ar in r ank e	ed
dar Mar.31 Jun.30 Sep.30 Dec.31 Full Full has decelerated somewhat in recent shares as a solid low-risk income play f 100 .18 .72 .00 .00 .20 .20 .20 .20 .80 company continues to be plagued by in- and Financial Strength (A++). Its 3.5 .18 .24 .24 .24 .24 .24 .96 Viagra (in Europe). These former block- Michael Ratty July 11, 201 J14 .26 .26 .26 .90 .96 Viagra (in Europe). These former block- Michael Ratty July 11, 201 Diluted earnings. Excl. non-rec. to change in shrs. Next egs. rpt. due late July. acqd. 4/03, included from 2nd qtr. (F) Wyeth stock's Price Stability Stock's Price Stability .91 Stock's Price Stability <td< td=""><td>2015</td><td></td><td></td><td></td><td></td><td></td><td>quar</td><td>ter of</td><td>2011</td><td>. While</td><td>e the</td><td>pace</td><td>of er</td><td>osion</td><td>(Ave</td><td>ragē)</td><td>for 7</td><td>Fimel</td><td>iness</td><td>.We</td><td>view 1</td><td>thes</td></td<>	2015						quar	ter of	2011	. While	e the	pace	of er	osion	(Ave	ragē)	for 7	Fimel	iness	.We	view 1	thes
Junite Initial Strength Junction Stren	Cal- endar						ĥas	dece	elerate	ed so	newł	hat i	in r	ecent	share	es as	a soli	i d low	-risk	incom	e pla	y fo
11 .20 .2	2010																					
112 .22 .22 .22 .22 .24 .	2011	.20	.20	.20	.20	.80	com	bany	contir	nues to	be be	plagu	ied b	y in-	and	Finar	ncial	Stren	gth (A++).	Its	
<u>114</u> .26 .26	2012 2013		.22				tens	e gen	eric d	ompeti	tion	on L	ipitor	and	divid	end y	ield is			avera	ige.	
Diluted earnings. Excl. non-rec. to change in shrs. Next egs. rpt. due late July. acqd. 4/03, included from 2nd qtr. (F) Wyeth Company's Financial Strength A++ ns/(losses): '98, 18¢; '99, (5¢); '00, (43¢); (B) Div'ds paid Mar., Jun, Sep., Dec.■ Div'd acqd. 10/09, included from 4th otr. (G) Stock's Price Stability 90	2014	.26	.26							•												
) Di iins/(los	luted sses): '9	earnings 8, 18¢:	. Excl. '99, (5¢) [.]	non-re '00. (43)	ec. to cl ¢); (B)	nange in Div'ds ກະ	shrs. Nex aid Mar.	kt egs. rp Jun. Se	t. due late p., Dec.∎	July. : Div'd :	acqd. 4/0 acqd. 10	03, incluo 0/09. in	ded from cluded f	2nd qtr. from 4th	(F) Wye	th Cou G) Sto				th	A++ 90

Price Growth Persistence 30 Earnings Predictability 65

To subscribe call 1-800-833-0046.